Ceftaroline for complicated skin and skin-structure infections

Bibliography

• McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006;12:1715-23
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG, Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42:647-56
   PubMed Web of Science ®Google Scholar
• Klevens RM, Morrison MA, Nadle J, Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17
   PubMed Web of Science ®Google Scholar
• Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998;42:1303-4
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Hanaki H, Ino T, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6
   PubMed Web of Science ®Google Scholar
• Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-55
   PubMedGoogle Scholar
• Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-32
   PubMed Web of Science ®Google Scholar
• CDC. Vancomycin-resistant Staphylococcus aureus–Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902
   PubMedGoogle Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Szczech LA, Benjamin DK Jr, Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-6
   PubMed Web of Science ®Google Scholar
• Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988;109:619-24
   PubMed Web of Science ®Google Scholar
• Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus – an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543-8
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Matsunaga N, Tawada H, TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427-37
   PubMed Web of Science ®Google Scholar
• Villegas-Estrada A, Lee M, Hesek D, Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc 2008;130:9212-13
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Sader HS. Ceftaroline activity tested against organisms causing skin and skin structure infections (SSSI) isolated in US and European medical centers in 2008 [abstract C1-160]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Sader HS, Fritsche TR, Kaniga K, Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-12
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:1153-5
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson L. In vitro activity of ceftaroline against CA-MRSA, VISA, VRSA and daptomycin-non-Susceptible Staphylococcus aureus [abstract C1-162]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009;53:4712-17
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007;51:3397-400
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Amador G, In vivo assessment of the activity of ceftaroline, linezolid and vancomycin in a rabbit osteomyelitis experimental model due to MRSA and GISA [abstract B-1358]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2007; Chicago, IL, USA
   Google Scholar
• McGee L, Biek D, Ge Y, In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009;53:552-6
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11
   PubMed Web of Science ®Google Scholar
• Hinshaw RR, Schaadt RD, Murray B, Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline [abstract C1-185]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Iizawa Y, Nagai J, Ishikawa T, In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004;10:146-56
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Critchley I, Bactericidal activity of ceftaroline combined with NXL104 against critical targeted organisms possessing various resistance mechanisms [abstract F1-1943]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Citron DM, Goldstein EJC. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria [abstract E-189]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Snydman DR, Jacobus NV, McDermott LA. In vitro activity of ceftaroline versus a broad spectrum of recent clinical anaerobic isolates [abstract E-203]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Ge Y, Redman R, Floren L, The pharmacokinetics and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous infusions [abstract A-1937]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27 – 30 September 2006; San Francisco, CA, USA
   Google Scholar
• Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M) [abstract A-1935]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA; 2006
   Google Scholar
• Riccobene T, Fang E, Thye D. Open-label pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in subjects with normal renal function or severe renal impairment [abstract A1-003]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Ge Y, Liao S, Thye DA, Talbot GH. Ceftaroline dose adjustment recommendations for subjects with mild or moderate renal impairment [abstract A-35]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2007; Chicago, IL, USA
   Google Scholar
• Van Wart SA, Forrest A, Bhavnani SM, Population pharmacokinetics of ceftaroline in healthy and renally impaired subjects [abstract A1-004]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Riccobene T, Fang E, Thye D. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline administered by intramuscular injection to healthy subjects [abstract A-1888]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Ge Y, Maynard D, Rickert DE. Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection. Antimicrob Agents Chemother 2009; doi:10.1128/AAC.00645-09
   Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, Evaluation of the efficacy of intramuscular administration of ceftaroline against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model [abstract B-1003]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006;50:1376-83
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against gram-positive organisms. Antimicrob Agents Chemother 2009;53:4537-9
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-16
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in complicated skin and skin structure infections [abstract L-1515a]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of America Annual Meeting; 25 – 28 October 2008; Washington, DC, USA
   Google Scholar
• Wilcox M, Corey R, Talbot GH, CANVAS-2: randomized, double-blinded, phase 3 study (p903-07) of the efficacy and safety of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infections [abstract P1792]. 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 16 – 19 May 2009; Helsinki, Finland
   Google Scholar
• Eckburg P, Friedland HD, Lee J, FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline vs ceftriaxone in community-acquired pneumonia [abstract L1-345a]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med 2009;361:787-94
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Ariano RE, Zelenitsky SA, Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009;53:1476-81
   PubMed Web of Science ®Google Scholar